RxDoctor Payments DataLook up a doctor →

Olivia Hightower, MD

Medical Oncology · Gulfport, MSNPI 1528228541

Payments from drug & device makers

$22,794in general payments, 2019–2025

Across 1,222 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Merck$2K
  • Genentech USA, Inc.$1K
  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Eisai Inc.$1K
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$21,39294%
  • Education$3031%
  • Other$1,0985%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis127$3,225
Merck97$1,892
Genentech USA, Inc.77$1,390
AstraZeneca(2 entities)80$1,331
Johnson & Johnson(2 entities)67$1,062
Eisai Inc.51$1,014
Lilly USA, LLC42$832
Daiichi Sankyo Inc.45$786
E.r. Squibb & Sons, L.L.C.51$718
Amgen42$701
Bristol Myers Squibb38$680
Pfizer41$671
Incyte Corporation45$670
Gilead(2 entities)18$404
Exelixis Inc.23$382
Bayer20$368
Puma Biotechnology, Inc.21$324
Adaptive Biotechnologies Corporation14$313
Tersera Therapeutics LLC12$309
Array Biopharma Inc16$296
Ipsen Biopharmaceuticals, Inc14$293
Takeda Pharmaceuticals U.S.A., Inc.14$291
Astellas Pharma US Inc15$280
Beigene USA, Inc.16$275
Regeneron Healthcare Solutions, Inc.12$255
Emmaus Medical, Inc.13$230
Karyopharm Therapeutics Inc.13$230
EMD Serono, Inc.13$224
Sanofi13$221
GSK12$208
AbbVie9$182
Stemline Therapeutics Inc.8$161
Rigel Pharmaceuticals, Inc.9$159
Taiho Oncology, Inc.6$121
Boehringer Ingelheim6$120
Alnylam Pharmaceuticals Inc.6$118
Seagen Inc.8$117
Pharmacosmos Therapeutics Inc.6$109
Sobi, Inc6$104
Pharmaessentia USA Corporation4$103
Invivyd Inc5$93
AVEO Pharmaceuticals, Inc.4$91
Coherus Oncology, Inc.5$86
Blueprint Medicines Corporation5$69
Morphosys, US Inc.4$68
Pharmacyclics LLC, An Abbvie Company4$64
Foundation Medicine, Inc.3$64
Lexicon Pharmaceuticals, Inc.4$62
Caris MPI, Inc.3$61
Genmab U.S., Inc.3$57
Clovis Oncology, Inc.4$56
Sanofi US Services Inc.1$54
CTI Biopharma Corp.3$50
Novocure Inc.2$44
AMAG Pharmaceuticals, Inc.3$41
Acceleron Pharma, Inc.2$40
Azurity Pharmaceuticals, Inc.2$36
Dendreon Pharmaceuticals LLC2$33
ADC Therapeutics America, Inc.2$32
Tactile Systems Technology Inc2$31

How this compares

$22,794 in reported general payments places this provider in the 65th percentile of 20 medical oncology providers in Mississippi.

See all medical oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$244,413
Medicare patients
593
Services billed
2,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide28$628,099
CalquenceAcalabrutinib Maleate34$483,358
XtandiEnzalutamide37$368,946
ImbruvicaIbrutinib46$323,099
VerzenioAbemaciclib21$297,257
PomalystPomalidomide12$276,090
JakafiRuxolitinib Phosphate12$194,340
KisqaliRibociclib Succinate13$180,820
IbrancePalbociclib12$180,281
Lenalidomide12$171,544
TasignaNilotinib Hcl13$115,595
HizentraImmun Glob G(Igg)/Pro/Iga 0-5036$110,261
EliquisApixaban122$95,917
XareltoRivaroxaban105$87,661
PromactaEltrombopag Olamine12$81,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$680$628,09928 claims
AstraZenecaCalquence$1,331$483,35834 claims
NovartisKisqali, Tasigna, Promacta$3,225$377,65338 claims
Astellas Pharma US IncXtandi, Myrbetriq$280$376,77252 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$64$323,09946 claims
Lilly USA, LLCVerzenio$832$297,25721 claims
PfizerIbrance, Eliquis$671$276,198134 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$718$276,09012 claims
Incyte CorporationJakafi$670$194,34012 claims
Johnson & JohnsonXarelto$1,062$87,661105 claims
AbbVieLinzess$182$43,25866 claims
GSKTrelegy Ellipta, Anoro Ellipta$208$28,01844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 20 medical oncology providers in Mississippi.

Other medical oncology in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →